The FDA just approved tirzepatide to lower the risk of heart attack and stroke in people with type 2 diabetes.
This approval is based on strong results from the SURPASS-CVOT clinical trial.
Louis shares that the FDA approved tirzepatide to lower heart attack and stroke risk in type 2 diabetes, based on SURPASS-CVOT. In 13,299 adults with established heart disease, tirzepatide was noninferior to dulaglutide for MACE (12.2% vs 13.1%, HR 0.92), without formally reaching superiority.
The FDA just approved tirzepatide to lower the risk of heart attack and stroke in people with type 2 diabetes.
This approval is based on strong results from the SURPASS-CVOT clinical trial.
The approval rests on SURPASS-CVOT, the first heart outcome trial to test an incretin drug against another active cardioprotective drug instead of placebo.
The trial
- 13,299 adults with type 2 diabetes + established heart disease
- Tirzepatide (up to 15mg) vs. dulaglutide (Trulicity) 1.5mg, weekly
- Double-blind, noninferiority design, median 4 years follow-up
- High-risk pop: avg. age 64, ~⅔ had coronary disease, ~20% prior stroke, on top of standard heart/diabetes meds
Headline result
- MACE (heart death, heart attack, or stroke): 12.2% tirzepatide vs. 13.1% dulaglutide
- HR 0.92 (95.3% CI 0.83–1.01)
✅ Noninferiority met (P=0.003)
❌ Superiority not formally reached (P=0.09), but every MACE component trended in tirzepatide’s favorWhy noninferiority still matters
- Dulaglutide already has proven heart benefit → matching it implies tirzepatide also beats placebo
Supporting data
- Broader 6-point cardiorenal outcome: 3.7% absolute risk reduction, NNT 27, favoring tirzepatide
- Also lower all-cause mortality & 4-point MACE vs. dulaglutide
- Indirect vs. placebo (via REWIND data): MACE HR 0.72, CV death/HF HR 0.70, all-cause death HR 0.61
- Earlier signals: SURPASS-4 (HR 0.74) & 7-trial meta-analysis (HR 0.80)
- Real-world 2026 cohort: MACE HR 0.68 vs. sitagliptin proxy
Safety: consistent with the #GLP class — mainly more GI effects (nausea, diarrhea, vomiting)
Bottom line: Tirzepatide now has robust evidence for heart protection in T2D + ASCVD, not just glucose and weight benefits.
📚 References
- Cardiovascular Outcomes with Tirzepatide vs Dulaglutide in T2D. N Engl J Med. 2025;393(24):2409-2420.
- Tirzepatide and Cardioprotection in T2D: Insights From SURPASS-CVOT. Diabetes Obes Metab. 2026;28(7):5413-5415.
- Cardiorenal Outcomes With Tirzepatide vs Dulaglutide.
- Indirect comparison analysis (SURPASS-CVOT + REWIND).
- SURPASS-4 trial.
- Meta-analysis of 7 SURPASS trials.
- 2026 real-world cohort (sitagliptin comparator).